{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:49:01Z","timestamp":1772754541348,"version":"3.50.1"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"project of Palacky university","award":["No. IGA_LF_2016_014"],"award-info":[{"award-number":["No. IGA_LF_2016_014"]}]},{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"crossref","award":["16-28375A"],"award-info":[{"award-number":["16-28375A"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s00280-016-3058-y","type":"journal-article","created":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T09:27:20Z","timestamp":1464773240000},"page":"1101-1111","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer"],"prefix":"10.1007","volume":"78","author":[{"given":"Radmila","family":"Lemstrova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bohuslav","family":"Melichar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Mohelnikova-Duchonova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,1]]},"reference":[{"issue":"6","key":"3058_CR1","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris","year":"1997","unstructured":"Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403\u20132413","journal-title":"J Clin Oncol"},{"issue":"6","key":"3058_CR2","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdv133","volume":"26","author":"G Deplanque","year":"2015","unstructured":"Deplanque G, Demarchi M, Hebbar M, Flynn P, Melichar B, Atkins J, Nowara E, Moy\u00e9 L, Piquemal D, Ritter D, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Hammel P (2015) A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Ann Oncol 26(6):1194\u20131200","journal-title":"Ann Oncol"},{"issue":"5","key":"3058_CR3","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/annonc\/mdv027","volume":"26","author":"CS Fuchs","year":"2015","unstructured":"Fuchs CS, Azevedo S, Okusaka T, Van Laethem JL, Lipton LR, Riess H, Szczylik C, Moore MJ, Peeters M, Bodoky G, Ikeda M, Melichar B, Nemecek R, Ohkawa S, \u015awieboda-Sadlej A, Tjulandin SA, Van Cutsem E, Loberg R, Haddad V, Gansert JL, Bach BA, Carrato A (2015) A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial. Ann Oncol 26(5):921\u2013927","journal-title":"Ann Oncol"},{"issue":"19","key":"3058_CR4","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardi\u00e8re C, Bennouna J, Bachet JB, Khemissa-Akouz F, P\u00e9r\u00e9-Verg\u00e9 D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M, Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817\u20131825","journal-title":"N Engl J Med"},{"issue":"18","key":"3058_CR5","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Hoff Von","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691\u20131703","journal-title":"N Engl J Med"},{"key":"3058_CR6","doi-asserted-by":"crossref","unstructured":"Bekaii-Saab T, Noonan AM, Lesinski G, Mikhail S, Ciombor K, Pant S, Aparo S, Tahiri S, Thompson A, Sexton J, Marshall JL, Mace T, Wu C, El-Rayes B, Timmers C, Geyer S, Zwiebel J, Villalona-Calero MA (2014) LBA19A multi-institutional randomized phase 2 trial of the oncolytic virus reolysin in the first line treatment metastatic adenokarcinoma of the pancreas (MAP). Ann Oncol 25(Suppl. 4):mdu438-19","DOI":"10.1093\/annonc\/mdu438.19"},{"issue":"5698","key":"3058_CR7","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/277665a0","volume":"277","author":"PB Schiff","year":"1979","unstructured":"Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277(5698):665\u2013667","journal-title":"Nature"},{"key":"3058_CR8","first-page":"2254","volume":"30","author":"F Lavelle","year":"1989","unstructured":"Lavelle F, Fizames C, Gueritte-Voegelein F, Guenard D, Potier P (1989) Experimental properties of RP 56976, a taxol derivative. Proc Am Assoc Cancer Res 30:2254","journal-title":"Proc Am Assoc Cancer Res"},{"issue":"18","key":"3058_CR9","first-page":"4845","volume":"51","author":"MC Bissery","year":"1991","unstructured":"Bissery MC, Gu\u00e9nard D, Gu\u00e9ritte-Voegelein F, Lavelle F (1991) Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 51(18):4845\u20134852","journal-title":"Cancer Res"},{"issue":"2","key":"3058_CR10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1185\/03007995.2012.756393","volume":"29","author":"WX Qi","year":"2013","unstructured":"Qi WX, Shen Z, Lin F, Sun YJ, Min DL, Tang LN, He AN, Yao Y (2013) Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. Curr Med Res Opin 29(2):117\u2013125","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"3058_CR11","first-page":"1851","volume":"56","author":"MV Blagosklonny","year":"1996","unstructured":"Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM (1996) Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 56(8):1851\u20131854","journal-title":"Cancer Res"},{"issue":"16","key":"3058_CR12","first-page":"4426","volume":"60","author":"Y Huang","year":"2000","unstructured":"Huang Y, Johnson KR, Norris JS, Fan W (2000) Nuclear factor-\u03baB\/I\u03baB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res 60(16):4426\u20134432","journal-title":"Cancer Res"},{"issue":"3","key":"3058_CR13","first-page":"337","volume":"80","author":"GN Kumar","year":"1993","unstructured":"Kumar GN, Walle UK, Bhalla KN, Walle T (1993) Binding of taxol to human plasma, albumin and alpha-1-acid glycoprotein. Res Commun Chem Pathol Pharmacol 80(3):337\u2013344","journal-title":"Res Commun Chem Pathol Pharmacol"},{"issue":"2","key":"3058_CR14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF00210785","volume":"14","author":"S Urien","year":"1996","unstructured":"Urien S, Barr\u00e9 J, Morin C, Paccaly A, Montay G, Tillement JP (1996) Docetaxel serum protein binding with high affinity to alpha1-acid glycoprotein. Invest New Drugs 14(2):147\u2013151","journal-title":"Invest New Drugs"},{"issue":"2","key":"3058_CR15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/clpt.2008.95","volume":"85","author":"SD Baker","year":"2009","unstructured":"Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A (2009) Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 85(2):155\u2013163","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"3058_CR16","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1211\/jpp\/61.08.0006","volume":"61","author":"T Tanino","year":"2009","unstructured":"Tanino T, Nawa A, Nakao M, Noda M, Fujiwara S, Iwaki M (2009) Organic anion transporting polypeptide 2 mediated uptake of paclitaxel and 2\u2032 ethylcarbonate linked paclitaxel in freshly isolated rat hepatocytes. J Pharm Pharmacol 61(8):1029\u20131035","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"3058_CR17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1023\/A:1022286422439","volume":"20","author":"JS Woo","year":"2003","unstructured":"Woo JS, Lee CH, Shim CK, Hwang SJ (2003) Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm Res 20(1):24\u201330","journal-title":"Pharm Res"},{"issue":"5","key":"3058_CR18","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/(SICI)1097-0215(19980529)76:5<702::AID-IJC15>3.0.CO;2-5","volume":"76","author":"GM Su","year":"1998","unstructured":"Su GM, Davey MW, Davey RA (1998) Induction of broad drug resistance in small cell lung cancer cells and its reversal by paclitaxel. Int J Cancer 76(5):702\u2013708","journal-title":"Int J Cancer"},{"issue":"11","key":"3058_CR19","first-page":"1195","volume":"2","author":"TA Brooks","year":"2003","unstructured":"Brooks TA, Minderman H, O\u2019Loughlin KL, Pera P, Ojima I, Baer MR, Bernacki RJ (2003) Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther 2(11):1195\u20131205","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"3058_CR20","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ijc.21013","volume":"116","author":"MT Huisman","year":"2005","unstructured":"Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH (2005) MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer 116(5):824\u2013829","journal-title":"Int J Cancer"},{"issue":"17","key":"3058_CR21","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1002\/rcm.2072","volume":"19","author":"J Guitton","year":"2005","unstructured":"Guitton J, Cohen S, Tranchand B, Vignal B, Droz JP, Guillaumont M, Manchon M, Freyer G (2005) Quantification of docetaxel and its main metabolites in human plasma by liquid chromatography\/tandem mass spectrometry. Rapid Commun Mass Spectrom 19(17):2419\u20132426","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"4","key":"3058_CR22","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2165\/00003088-199427040-00002","volume":"27","author":"DS Sonnichsen","year":"1994","unstructured":"Sonnichsen DS, Relling MV (1994) Clinical pharmacokinetics of paclitaxel. Clin Pharmacokinet 27(4):256\u2013269","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"3058_CR23","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00280-002-0560-1","volume":"51","author":"SS Shord","year":"2012","unstructured":"Shord SS, Faucette SR, Gillenwater HH, Pescatore SL, Hawke RL, Socinski MA, Lindley C (2012) Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 51(4):328\u2013336","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"3058_CR24","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1158\/2159-8290.CD-11-0242","volume":"2","author":"KK Frese","year":"2012","unstructured":"Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, Tuveson DA (2012) nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov 2(3):260\u2013269","journal-title":"Cancer Discov"},{"issue":"4","key":"3058_CR25","first-page":"1013","volume":"4","author":"N Sawada","year":"1998","unstructured":"Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol\/taxotere in human cancer xenografts. Clin Cancer Res 4(4):1013\u20131019","journal-title":"Clin Cancer Res"},{"issue":"13","key":"3058_CR26","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","volume":"37","author":"H Gelderblom","year":"2001","unstructured":"Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37(13):1590\u20131598","journal-title":"Eur J Cancer"},{"issue":"7","key":"3058_CR27","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.1990.8.7.1263","volume":"8","author":"RB Weiss","year":"1990","unstructured":"Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR Jr, Van Echo DA, Von Hoff DD, Leyland-Jones B (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8(7):1263\u20131268","journal-title":"J Clin Oncol"},{"issue":"7","key":"3058_CR28","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2165\/00003088-200342070-00005","volume":"42","author":"A Tije Ten","year":"2003","unstructured":"Ten Tije A, Verweij J, Loos WJ, Sparreboom A (2003) Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 42(7):665\u2013685","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"3058_CR29","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/sj.bjc.6690696","volume":"81","author":"O Tellingen van","year":"1999","unstructured":"van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH (1999) Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 81(2):330","journal-title":"Br J Cancer"},{"issue":"8","key":"3058_CR30","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1517\/14656566.7.8.1041","volume":"7","author":"WJ Gradishar","year":"2006","unstructured":"Gradishar WJ (2006) Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 7(8):1041\u20131053","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"3058_CR31","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1158\/1078-0432.CCR-03-0655","volume":"10","author":"TY Kim","year":"2004","unstructured":"Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, Kim NK, Bang YJ (2004) Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 10(11):3708\u20133716","journal-title":"Clin Cancer Res"},{"key":"3058_CR32","first-page":"49","volume":"7","author":"HI Chang","year":"2012","unstructured":"Chang HI, Yeh MK (2012) Clinically-proven liposome-based drug delivery: formulation, characterization and therapeutic efficacy. Int J Nanomed 7:49\u201360","journal-title":"Int J Nanomed"},{"issue":"10","key":"3058_CR33","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/0959-8049(96)00160-8","volume":"32","author":"N Gebbia","year":"1996","unstructured":"Gebbia N, Gebbia V (1996) Single agent paclitaxel in the treatment of unresectable and\/or metastatic pancreatic adenocarcinoma. Eur J Cancer 32(10):1822\u20131823","journal-title":"Eur J Cancer"},{"issue":"6","key":"3058_CR34","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1200\/JCO.1997.15.6.2414","volume":"15","author":"RP Whitehead","year":"1997","unstructured":"Whitehead RP, Jacobson J, Brown TD, Taylor SA, Weiss GR, Macdonald JS (1997) Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study. J Clin Oncol 15(6):2414\u20132419","journal-title":"J Clin Oncol"},{"issue":"8","key":"3058_CR35","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00001813-200009000-00006","volume":"11","author":"H Oettle","year":"2000","unstructured":"Oettle H, Arnold D, Esser M, Huhn D, Riess H (2000) Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 11(8):635\u2013638","journal-title":"Anticancer Drugs"},{"issue":"12","key":"3058_CR36","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/jjco\/hyq117","volume":"40","author":"T Shukuya","year":"2010","unstructured":"Shukuya T, Yasui H, Boku N, Onozawa Y, Fukutomi A, Yamazaki K, Taku K, Kojima T, Machida N (2010) Weekly paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study. Jpn J Clin Oncol 40(12):1135\u20131138","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"3058_CR37","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10147-011-0220-8","volume":"16","author":"S Maeda","year":"2011","unstructured":"Maeda S, Motoi F, Onogawa T, Morikawa T, Shigeru O, Sakata N, Takadate T, Naitoh T, Rikiyama T, Katayose Y, Egawa S, Unno M (2011) Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study. Int J Clin Oncol 16(5):539\u2013545","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"3058_CR38","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00280-008-0822-7","volume":"63","author":"YJ Kim","year":"2009","unstructured":"Kim YJ, Bang S, Park JY, Park SW, Chung JB, Song SY (2009) Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer. Cancer Chemother Pharmacol 63(3):529\u2013533","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"3058_CR39","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1200\/JCO.1999.17.6.1779","volume":"17","author":"N Androulakis","year":"1999","unstructured":"Androulakis N, Kourousis C, Dimopoulos MA, Samelis G, Kakolyris S, Tsavaris N, Genatas K, Aravantinos G, Papadimitriou C, Karabekios S, Stathopoulos GP, Georgoulias V (1999) Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. J Clin Oncol 17(6):1779","journal-title":"J Clin Oncol"},{"issue":"8","key":"3058_CR40","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0959-8049(00)00072-1","volume":"36","author":"P Rougier","year":"2000","unstructured":"Rougier P, Adenis A, Ducreux M, de Forni M, Bonneterre J, Dembak M, Clouet P, Lebecq A, Baille P, Lefresne-Soulas F, Blanc C, Armand JP (2000) A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 36(8):1016\u20131025","journal-title":"Eur J Cancer"},{"issue":"3\u20134","key":"3058_CR41","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/sj.bjc.6690375","volume":"80","author":"S Okada","year":"1999","unstructured":"Okada S, Sakata Y, Matsuno S, Kurihara M, Sasaki Y, Ohashi Y, Taguchi T (1999) Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Br J Cancer 80(3\u20134):438","journal-title":"Br J Cancer"},{"issue":"1","key":"3058_CR42","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00280-007-0473-0","volume":"61","author":"RL Fine","year":"2008","unstructured":"Fine RL, Fogelman DR, Schreibman SM, Desai M, Sherman W, Strauss J, Guba S, Andrade R, Chabot J (2008) The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol 61(1):167\u2013175","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"3058_CR43","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00280-011-1717-6","volume":"69","author":"N Xenidis","year":"2012","unstructured":"Xenidis N, Chelis L, Amarantidis K, Chamalidou E, Dimopoulos P, Courcoutsakis N, Tentes A, Chiotis A, Prassopoulos P, Kakolyris S (2012) Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study. Cancer Chemother Pharmacol 69(2):477\u2013484","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"3058_CR44","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00280-011-1704-y","volume":"69","author":"A Jesus-Acosta De","year":"2012","unstructured":"De Jesus-Acosta A, Oliver GR, Blackford A, Kinsman K, Flores EI, Wilfong LS, Zheng L, Donehower RC, Cosgrove D, Laheru D, Le DT, Chung K, Diaz LA Jr (2012) A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol 69(2):415\u2013424","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"3058_CR45","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00280-011-1705-x","volume":"69","author":"HK Dakik","year":"2012","unstructured":"Dakik HK, Moskovic DJ, Carlson PJ, Tamm EP, Qiao W, Wolff RA, Abbruzzese JL, Fogelman DR (2012) The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol 69(2):425\u2013430","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"3058_CR46","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00280-011-1680-2","volume":"69","author":"M Reni","year":"2012","unstructured":"Reni M, Cereda S, Rognone A, Belli C, Ghidini M, Longoni S, Fugazza C, Rezzonico S, Passoni P, Slim N, Balzano G, Nicoletti R, Cappio S, Doglioni C, Villa E (2012) A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). Cancer Chemother Pharmacol 69(1):115\u2013123","journal-title":"Cancer Chemother Pharmacol"},{"issue":"36","key":"3058_CR47","doi-asserted-by":"crossref","first-page":"9250","DOI":"10.1200\/JCO.2005.02.1980","volume":"23","author":"MP Lutz","year":"2005","unstructured":"Lutz MP, Van Cutsem E, Wagener T, Van Laethem JL, Vanhoefer U, Wils JA, Gamelin E, Koehne CH, Arnaud JP, Mitry E, Husseini F, Reichardt P, El-Serafi M, Etienne PL, Lingenfelser T, Praet M, Genicot B, Debois M, Nordlinger B, Ducreux MP, EuropeanOrganisation for Research and Treatment of Cancer Gastrointestinal Group (2005) Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group. J Clin Oncol 23(36):9250\u20139256","journal-title":"J Clin Oncol"},{"issue":"5","key":"3058_CR48","first-page":"1038","volume":"8","author":"NK Ibrahim","year":"2002","unstructured":"Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA (2002) Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8(5):1038\u20131044","journal-title":"Clin Cancer Res"},{"issue":"34","key":"3058_CR49","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","volume":"29","author":"DD Hoff Von","year":"2011","unstructured":"Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial. J Clin Oncol 29(34):4548\u20134554","journal-title":"J Clin Oncol"},{"key":"3058_CR50","doi-asserted-by":"crossref","unstructured":"Von Hoff D et al (2013) Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates. J Clin Oncol 31(15):(suppl; abstr 4005^)","DOI":"10.1200\/jco.2013.31.15_suppl.4005"},{"issue":"6","key":"3058_CR51","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00280-012-1979-7","volume":"70","author":"AH Ko","year":"2012","unstructured":"Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA (2012) A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. Cancer Chemother Pharmacol 70(6):875\u2013881","journal-title":"Cancer Chemother Pharmacol"},{"key":"3058_CR52","doi-asserted-by":"crossref","unstructured":"De Jesus-Acosta A, O\u00b4Dwyer P, Ramanathan R et al (2014) A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients with untreated metastatic pancreatic ductal adenocarcinoma (PDA). Poster presented at: 2014 Gastrointestinal Cancers Symposium (ASCO-GI) 2014; January 16-18; San Francisco, CA, USA","DOI":"10.1200\/jco.2014.32.3_suppl.257"},{"key":"3058_CR53","doi-asserted-by":"crossref","unstructured":"Sigal D et al. (2013) Association of 2-O, 3-O desulfated heparin (ODSH) plus combination gemcitabine (G)\/nab-paclitaxel (A) with preliminary benefit in untreated metastatic pancreatic cancer. J Clin Oncol 31:(suppl 4; abstr 284)","DOI":"10.1200\/jco.2013.31.4_suppl.284"},{"key":"3058_CR54","unstructured":"Cubillo A, Jameson M, Grande E et al (2014) A phase 1b study of the anti-cancer stem cell agent demcizumab (DEM, anti-DLL4) and gemcitabine (GEM) with or without nab-paclitaxel in patients with pancreatic cancer. Poster presented at: 2014 Gastrointestinal Cancers Symposium (ASCO-GI) 2014; January 16-18; San Francisco, CA, USA"},{"key":"3058_CR55","doi-asserted-by":"crossref","unstructured":"Isacoff WH, Reber HA, Hines OJ et al (2012) Metronomic therapy with 5-FU, weekly nab-paclitaxel, leucovorin, and oxaliplatin, plus bevacizumab for advanced pancreatic cancer: a phase II study. In: Proceedings of the 48th annual meeting of the American Society of Clinical Oncology (ASCO) 2012; June 1\u20135; Chicago, IL, USA: Abstract #e14582. http:\/\/abstract.asco.org\/AbstView_114_100395.html","DOI":"10.1200\/jco.2012.30.15_suppl.e14582"},{"issue":"2","key":"3058_CR56","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3109\/07357900903179591","volume":"28","author":"MW Saif","year":"2009","unstructured":"Saif MW, Podoltsev NA, Rubin MS, Figueroa JA, Lee MY, Kwon J, Rowen E, Yu J, Kerr RO (2009) Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer. Cancer Invest 28(2):186\u2013194","journal-title":"Cancer Invest"},{"issue":"5","key":"3058_CR57","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/annonc\/mdr379","volume":"23","author":"JM L\u00f6hr","year":"2012","unstructured":"L\u00f6hr JM, Haas SL, Bechstein WO, Bodoky G, Cwiertka K, Fischbach W, F\u00f6lsch UR, J\u00e4ger D, Osinsky D, Prausova J, Schmidt WE, Lutz MP, CT4001 Study Group (2012) Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. Ann Oncol 23(5):1214\u20131222","journal-title":"Ann Oncol"},{"issue":"6","key":"3058_CR58","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.pan.2013.09.005","volume":"13","author":"B Mohelnikova-Duchonova","year":"2013","unstructured":"Mohelnikova-Duchonova B, Melichar B (2013) Human equilibrative nucleoside transporter 1 (hENT1): do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients? Pancreatology 13(6):558\u2013563","journal-title":"Pancreatology"},{"issue":"8","key":"3058_CR59","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2217\/pgs.14.80","volume":"15","author":"R Lemstrova","year":"2014","unstructured":"Lemstrova R, Melichar B, Mohelnikova-Duchonova B (2014) Role of solute carrier transporters in pancreatic cancer: a review. Pharmacogenomics 15(8):1133\u20131145","journal-title":"Pharmacogenomics"},{"issue":"2","key":"3058_CR60","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/107327480301000207","volume":"10","author":"H Thomas","year":"2003","unstructured":"Thomas H, Coley HM (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10(2):159","journal-title":"Cancer Control"},{"issue":"2","key":"3058_CR61","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/MPA.0b013e3181bab6c2","volume":"39","author":"B Mohelnikova-Duchonova","year":"2010","unstructured":"Mohelnikova-Duchonova B, Vrana D, Holcatova I, Ryska M, Smerhovsky Z, Soucek P (2010) CYP2A13, ADH1B, and ADH1C gene polymorphisms and pancreatic cancer risk. Pancreas 39(2):144\u2013148","journal-title":"Pancreas"},{"issue":"3","key":"3058_CR62","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00280-013-2246-2","volume":"72","author":"B Mohelnikova-Duchonova","year":"2013","unstructured":"Mohelnikova-Duchonova B, Brynychova V, Hlavac V, Kocik M, Oliverius M, Hlavsa J, Honsova E, Mazanec J, Kala Z, Melichar B, Soucek P (2013) The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer. Cancer Chemother Pharmacol 72(3):669\u2013682","journal-title":"Cancer Chemother Pharmacol"},{"key":"3058_CR63","unstructured":"http:\/\/www.proteinatlas.org\/ENSG00000137204-SLC22A7\/tissue\/pancreas"},{"issue":"4","key":"3058_CR64","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.18632\/oncotarget.2946","volume":"6","author":"JA McCarroll","year":"2015","unstructured":"McCarroll JA, Sharbeen G, Liu J, Youkhana J, Goldstein D, McCarthy N, Limbri LF, Dischl D, Ceyhan GO, Erkan M, Johns AL, Biankin AV, Kavallaris M, Phillips PA (2015) III-Tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer. Oncotarget 6(4):2235\u20132249","journal-title":"Oncotarget"},{"issue":"47","key":"3058_CR65","doi-asserted-by":"crossref","first-page":"7280","DOI":"10.1038\/sj.onc.1206934","volume":"22","author":"GA Orr","year":"2003","unstructured":"Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB (2003) Mechanisms of taxol resistance related to microtubules. Oncogene 22(47):7280\u20137295","journal-title":"Oncogene"},{"issue":"5","key":"3058_CR66","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1172\/JCI119642","volume":"100","author":"M Kavallaris","year":"1997","unstructured":"Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, Horwitz SB (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Investig 100(5):1282\u20131293","journal-title":"J Clin Investig"},{"issue":"53","key":"3058_CR67","doi-asserted-by":"crossref","first-page":"8581","DOI":"10.1038\/sj.onc.1207113","volume":"22","author":"DC Altieri","year":"2003","unstructured":"Altieri DC (2003) Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22(53):8581\u20138589","journal-title":"Oncogene"},{"issue":"2","key":"3058_CR68","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/1097-0142(20010715)92:2<271::AID-CNCR1319>3.0.CO;2-0","volume":"92","author":"K Satoh","year":"2001","unstructured":"Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T (2001) Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 92(2):271\u2013278","journal-title":"Cancer"},{"issue":"2","key":"3058_CR69","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.surg.2004.05.023","volume":"136","author":"K Kami","year":"2004","unstructured":"Kami K, Doi R, Koizumi M, Toyoda E, Mori T, Ito D, Fujimoto K, Wada M, Miyatake S, Imamura M (2004) Survivin expression is a prognostic marker in pancreatic cancer patients. Surgery 136(2):443\u2013448","journal-title":"Surgery"},{"issue":"6","key":"3058_CR70","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00268-011-1345-7","volume":"36","author":"S Ekeblad","year":"2012","unstructured":"Ekeblad S, Lejonklou MH, St\u00e5lberg P, Skogseid B (2012) Prognostic relevance of survivin in pancreatic endocrine tumors. World J Surg 36(6):1411\u20131418","journal-title":"World J Surg"},{"issue":"20","key":"3058_CR71","first-page":"3063","volume":"18","author":"YQ Ren","year":"2014","unstructured":"Ren YQ, Zhang HY, Su T, Wang XH, Zhang L (2014) Clinical significance of serum survivin in patients with pancreatic ductal adenocarcinoma. Eur Rev Med Pharmacol Sci 18(20):3063\u20133068","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"3058_CR72","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12957-015-0605-7","volume":"13","author":"H Dong","year":"2015","unstructured":"Dong H, Qian D, Wang Y, Meng L, Chen D, Ji X, Feng W (2015) Survivin expression and serum levels in pancreatic cancer. World J Surg Oncol 13(1):189","journal-title":"World J Surg Oncol"},{"issue":"6","key":"3058_CR73","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1053\/j.gastro.2012.11.037","volume":"144","author":"MV Apte","year":"2013","unstructured":"Apte MV, Wilson JS, Lugea A, Pandol SJ (2013) A starring role for stellate cells in the pancreatic cancer microenvironment. Gastroenterology 144(6):1210\u20131219","journal-title":"Gastroenterology"},{"issue":"6","key":"3058_CR74","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1159\/000320711","volume":"10","author":"S Dun\u00e9r","year":"2010","unstructured":"Dun\u00e9r S, Lopatko Lindman J, Ansari D, Gundewar C, Andersson R (2010) Pancreatic cancer: the role of pancreatic stellate cells in tumor progression. Pancreatology 10(6):673\u2013681","journal-title":"Pancreatology"},{"issue":"12","key":"3058_CR75","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/nrc949","volume":"2","author":"N Bardeesy","year":"2012","unstructured":"Bardeesy N, DePinho RA (2012) Pancreatic cancer biology and genetics. Nat Rev Cancer 2(12):897\u2013909","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"3058_CR76","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/bjc.2015.220","volume":"113","author":"I Lohse","year":"2015","unstructured":"Lohse I, Borgida A, Cao P, Cheung M, Pintilie M, Bianco T, Holter S, Ibrahimov E, Kumareswaran R, Bristow RG, Tsao MS, Gallinger S, Hedley DW (2015) BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. Br J Cancer 113(3):425\u2013432","journal-title":"Br J Cancer"},{"issue":"6","key":"3058_CR77","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/bjc.2014.418","volume":"111","author":"T Golan","year":"2014","unstructured":"Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, Aderka D, Paluch-Shimon S, Kaufman B, Gershoni-Baruch R, Hedley D, Moore MJ, Friedman E, Gallinger S (2014) Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 111(6):1132\u20131138","journal-title":"Br J Cancer"},{"key":"3058_CR78","doi-asserted-by":"crossref","unstructured":"Mohelnikova-Duchonova B, Kocik M, Duchonova B, Brynychova V, Oliverius M, Hlavsa J, Honsova E, Mazanec J, Kala Z, Ojima I, Hughes DJ, Doherty JE, Murray HA, Crockard MA, Lemstrova R, Soucek P (2016) Hedgehog pathway overexpression in pancreatic cancer is abrogated by new generation taxoid SB-T-1216. Pharmacogenomics J (in press)","DOI":"10.1038\/tpj.2016.55"},{"issue":"2","key":"3058_CR79","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/COC.0b013e3181a31920","volume":"33","author":"AP Lam","year":"2010","unstructured":"Lam AP, Sparano JA, Vinciguerra V, Ocean AJ, Christos P, Hochster H, Camacho F, Goel S, Mani S, Kaubisch A (2010) Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma. Am J Clin Oncol 33(2):121","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"3058_CR80","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1179\/joc.2008.20.4.509","volume":"20","author":"S Cereda","year":"2008","unstructured":"Cereda S, Reni M (2008) Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer. J Chemother 20(4):509\u2013512","journal-title":"J Chemother"},{"issue":"6B","key":"3058_CR81","first-page":"3583","volume":"22","author":"KN Syrigos","year":"2001","unstructured":"Syrigos KN, Michalaki B, Alevyzaki F, Machairas A, Mandrekas D, Kindilidis K, Karatzas G (2001) A phase-II study of liposomal doxorubicin and docetaxel in patients with advanced pancreatic cancer. Anticancer Res 22(6B):3583\u20133588","journal-title":"Anticancer Res"},{"issue":"3","key":"3058_CR82","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000074474","volume":"65","author":"BP Schneider","year":"2003","unstructured":"Schneider BP, Ganjoo KN, Seitz DE, Picus J, Fata F, Stoner C, Calley C, Loehrer PJ (2003) Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study. Oncology 65(3):218\u2013223","journal-title":"Oncology"},{"issue":"7","key":"3058_CR83","first-page":"2905","volume":"30","author":"MW Saif","year":"2010","unstructured":"Saif MW, Syrigos K, Penney R, Kaley K (2010) Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study. Anticancer Res 30(7):2905\u20132909","journal-title":"Anticancer Res"},{"issue":"2","key":"3058_CR84","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/COC.0b013e3182436e8c","volume":"36","author":"PJ Hosein","year":"2013","unstructured":"Hosein PJ, de Lima LG, Pastorini VH Jr, Gomez C, Macintyre J, Zayas G, Reis I, Montero AJ, Merchan JR, Rocha Lima CM (2013) A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol 36(2):151\u2013156","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"3058_CR85","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00280-016-2981-2","volume":"77","author":"SJ Cohen","year":"2016","unstructured":"Cohen SJ, O\u2019Neil BH, Berlin J, Ames P, McKinley M, Horan J, Catalano PM, Davies A, Weekes CD, Leichman L (2016) A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study. Cancer Chemother Pharmacol 77(4):693\u2013701","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3058-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-016-3058-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3058-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T22:45:59Z","timestamp":1656629159000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-016-3058-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,1]]},"references-count":85,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["3058"],"URL":"https:\/\/doi.org\/10.1007\/s00280-016-3058-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,1]]}}}